Affimed N.V.
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Values in USD · ADR · Reports in EUR
Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE ® ) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE ® are generated on the Company’s proprietary ROCK ® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.
Did you know?
Capital expenditures increased by 491% from FY22 to FY23.
Current Price
—
Profile
Valuation (TTM)
Market Cap—
P/E—
EV—
P/B—
Shares Out—
P/Sales—
Revenue—
EV/EBITDA—
Affimed N.V. (AFMD) Stock Analysis
Market Cap—
Current Price—
P/E Ratio—
Forward P/E—
PEG Ratio—
EPS—
Book Value—
P/B Ratio—
AFMD Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Cash: 21M
Revenue
2M
FY17
27M
FY18
24M
FY19
35M
FY20
46M
FY21
44M
FY22
9M
FY23
Net Income
—
FY17
—
FY18
—
FY19
—
FY20
—
FY21
—
FY22
—
FY23
Did you know?
AFMD's revenue grew at a 25.0% CAGR over the last 6 years.
Affimed N.V. (AFMD) Financial Summary
Affimed N.V. (AFMD) is a Healthcare company in the Biotechnology industry, listed on NASDAQ..
..
AFMD Key Financial Metrics
| Metric | Value |
|---|
AFMD Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY17 | $2.41M | $-36.28M |
| FY18 | $27.28M | $-22.39M |
| FY19 | $24.03M | $-36.37M |
| FY20 | $34.59M | $-50.45M |
| FY21 | $45.87M | $-65.37M |
| FY22 | $43.99M | $-91.49M |
| FY23 | $9.19M | $-117.71M |
About Affimed N.V.
Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE ® ) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE ® are generated on the Company’s proprietary ROCK ® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.